PMID- 38304999
OWN - NLM
STAT- MEDLINE
DCOM- 20240403
LR  - 20240409
IS  - 1873-474X (Electronic)
IS  - 0736-5748 (Linking)
VI  - 84
IP  - 2
DP  - 2024 Apr
TI  - Agmatine ameliorates valproic acid-induced depletion of parvalbumin-positive 
      neuron.
PG  - 134-142
LID - 10.1002/jdn.10314 [doi]
AB  - Autism spectrum disorder (ASD) is a widespread neurodevelopmental disorder with 
      unknown etiology. Dysfunction of several brain areas including the prefrontal 
      cortex (PFC), hippocampus, and cerebellum is involved in cognitive and behavioral 
      deficits associated with ASD. Several studies have reported a reduction in the 
      number of parvalbumin-immunoreactive (PV(+)) neurons in brain areas of ASD 
      patients and animal models such as a shank mutant mouse model and rodents 
      receiving fetal valproic acid (VPA) administration. Developing therapeutic 
      interventions that restore PV interneurons can be the future therapeutic approach 
      to ASD. The present study examined the possible effect of agmatine (AG), an 
      endogenous NMDA antagonist, on the number of PV(+) neurons in a VPA animal model 
      of autism. The therapeutic effects of AG in ameliorating ASD-like behaviors were 
      previously reported in VPA rats. AG was gavaged at dosages of 0.001, 0.01, and 
      0.1 mg/kg from gestational day (GD) 6.5 to 18.5, and the number of PV 
      interneurons was analyzed by immunohistochemistry in the 1-month-old rats. 
      Prenatal VPA (GD 12.5) or AG led to a decrease of PV neurons in the PFC, Cornu 
      ammonia (CA1), and molecular layers (MLs) of the cerebellum. However, exposure to 
      AG restored the PV population induced by VPA. AG may modify underlying neuronal 
      mechanisms resulting in the increased survival or restoration of the PV 
      population.
CI  - (c) 2024 International Society for Developmental Neuroscience.
FAU - Khoram-Abadi, Khadijeh Mirzaee
AU  - Khoram-Abadi KM
AD  - Student Research Committee, Kerman University of Medical Sciences, Kerman, Iran.
AD  - Department of Anatomical Sciences, Afzalipour School of Medicine, Kerman 
      University of Medical Sciences, Kerman, Iran.
FAU - Basiri, Mohsen
AU  - Basiri M
AD  - Department of Anatomical Sciences, Afzalipour School of Medicine, Kerman 
      University of Medical Sciences, Kerman, Iran.
FAU - Nemati, Mozhdeh
AU  - Nemati M
AD  - Neuroscience Research Center, Institute of Neuropharmacology, Department of 
      Physiology and Pharmacology, Afzalipour School of Medicine, Kerman University of 
      Medical Sciences, Kerman, Iran.
FAU - Nozari, Masoumeh
AU  - Nozari M
AD  - Neuroscience Research Center, Institute of Neuropharmacology, Department of 
      Physiology and Pharmacology, Afzalipour School of Medicine, Kerman University of 
      Medical Sciences, Kerman, Iran.
LA  - eng
GR  - 98001159/Kerman University of Medical Sciences/
PT  - Journal Article
DEP - 20240202
PL  - United States
TA  - Int J Dev Neurosci
JT  - International journal of developmental neuroscience : the official journal of the 
      International Society for Developmental Neuroscience
JID - 8401784
RN  - 70J407ZL5Q (Agmatine)
RN  - 0 (Parvalbumins)
RN  - 614OI1Z5WI (Valproic Acid)
SB  - IM
MH  - Animals
MH  - Female
MH  - Humans
MH  - Infant
MH  - Mice
MH  - Pregnancy
MH  - Rats
MH  - *Agmatine/therapeutic use
MH  - *Autism Spectrum Disorder/chemically induced
MH  - Behavior, Animal
MH  - Disease Models, Animal
MH  - Neurons
MH  - *Parvalbumins/metabolism
MH  - *Prenatal Exposure Delayed Effects/chemically induced
MH  - *Valproic Acid/adverse effects
OTO - NOTNLM
OT  - agmatine
OT  - autism
OT  - parvalbumin
OT  - rat
OT  - valproic acid
EDAT- 2024/02/02 06:43
MHDA- 2024/04/03 06:44
CRDT- 2024/02/02 04:42
PHST- 2023/12/08 00:00 [revised]
PHST- 2023/10/06 00:00 [received]
PHST- 2023/12/13 00:00 [accepted]
PHST- 2024/04/03 06:44 [medline]
PHST- 2024/02/02 06:43 [pubmed]
PHST- 2024/02/02 04:42 [entrez]
AID - 10.1002/jdn.10314 [doi]
PST - ppublish
SO  - Int J Dev Neurosci. 2024 Apr;84(2):134-142. doi: 10.1002/jdn.10314. Epub 2024 Feb 
      2.